Biocompatible Polyurethane-Based Hydrogel

1981. "HYPOL® Hydrophilic Polymers Toxicological Data," W. R. Grace & Co. Report.

Braatz, J.A. and C.L. Kehr. 1992. "Biocompatible Polyurea-Urethane Hydrated Polymers," U.S. patent 5,175,229.

Braatz, J.A. , A.H. Heifetz and C.L. Kehr. 1992. "A New Hydrophilic Polymer for Biomaterial Coatings with Low Protein Adsorption," J. Biomater. Sci. Polymer Edn., 3(6):451-462.

Braatz, J.A. , A.H. Heifetz , C.L. Kehr and R.A. Wolfe. 1992. "Protein Non-Adsorptive Polyurea-Urethane Polymer Coated Devices," U.S. patent 5,169,720.

Peppas, N.A. 1986. Hydrogels in Medicine and Pharmacy. Vol. I, Fundamentals . Boca Raton, FL: CRC Press, Inc.

Peppas, N.A. 1987. Hydrogels in Medicine and Pharmacy. Vol. II, Polymers . Boca Raton, FL: CRC Press, Inc.

Peppas, N.A. 1987. Hydrogels in Medicine and Pharmacy. Vol. III, Properties and Applications Boca Raton, FL: CRC Press, Inc.

Braatz, J.A. 1993. "A Simple Method for Determining Water-Induced Gelling Times of Isocyanate Prepolymers," J. Appl. Polym. Sci., 50(9): 1545-1554.

Braatz, J.A. and C.L. Kehr. 1989. "Contact Lenses Based on Biocompatible Polyurethane Polyurea-Urethane Hydrated Polymers," U.S. patent 4,886,866.

Bowers, R.W.J. and B.J. Tighe. 1987. "Studies of the Ocular Compatibility of Hydrogels. A Review of the Clinical Manifestations of Spoliation," Biomaterials, 8:83-89.

Hoffbrand, A.V. 1980. In Iron in Biochemistry and Medicine, II, A. Jacobs and M. Worwood , eds., London and New York: Academic Press, pp. 499-527.

Whitten, C.F. , G.W. Gibson , M.H. Good , J.F. Goodwin and A.J. Bough. 1965. "Studies in Acute Iron Poisoning. I. Desferrioxamine in the Treatment of Acute Iron Poisoning: Clinical Observations, Experimental Studies, and Theoretical Considerations;' Pediatrics, 36(3):322-335.

Whitten, C.F. , Y. Chen and G.W. Gibson. 1966. "Studies in Acute Iron Poi. soning. II. Further Observations on Desferrioxamine in the Treatment of Acute Experimental Iron Poisoning;' Pediatrics, 38(1):102-110.

Westlin, W.F. 1966. "Deferoxamine in the Treatment of Acute Iron Poisoning. Clinical Experiences with 172 Children," Clin. Pediatr., 5(9):531-535.

Oliveri, N.F. , J.R. Buncic , E. Chew , T. Gallant , R.V. Harrison , N. Keenan , W. Logan , D. Mitchell , G. Ricci , B. Skarf , M. Taylor and M.H. Freedman. 1986. "Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions," N. Engl. J. Med., 314(14):869-873.

Hallaway, P.E. , J.W. Eaton , S.S. Panter and B.E. Hedlund. 1989. "Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers," Proc. Natl. Acad. Sci. USA, 86:10108-10112.

Humphries, M.J. , K. Olden and K.M. Yamada. 1986. "A Synthetic Peptide from Fibronectin Inhibits Experimental Metastasis of Murine Melanoma Cells ;' Science, 223:467-470.

Humphries, M.J. , K.M. Yamada and K. Olden. 1988. "Investigations of the Biological Effects of Anti-Cell Adhesive Synthetic Peptides That Inhibit Experimental Metastasis of B16-F10 Murine Melanoma Cells;' J. Clin. Invest. , 81:782-790.

Braatz, J.A. , Y. Yasuda , K. Olden , K.M. Yamada and A.H. Heifetz. 1993. "Functional Peptide-Polyurethane Conjugates with Extended Circulatory Half-Lives," Bioconj. Chem., 4:262-267.

Abuchowski, A. , T van Es , N.C. Palczuk and F.F. Davis. 1977. "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol," J. Biol. Chem.,252:3578-3581.

Davis, F.F. , T van Es and N.C. Palczuk. 1979. "Non-Immunogenic Polypeptides," U.S. patent 4,179,337.

Hershfield, M.S. et al. 1987. "Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol-Modified Adenosine Deaminase;' N. Engl. J. Med., 316:589-596.

Chun, J.D. , N. Lee , R.H. Kobayashi , S. Chaffee , M.S. Hershfield and E.R. Steihm. 1993. "Suppression of an Antibody to Adenosine-Deaminase (ADA) in an ADA-Deficient Patient Receiving Polyethylene Glycol Modified Adenosine Deaminase;' Ann. Allergy (US), 70(6):462-466.

Blaese, R.M. 1993. "Development of Gene Therapy for Immunodeficiency: Adenosine Deaminase Deficiency;' Pediatr. Res., 33(1 Suppl.):S49-S53.

Katre, N.V. , M.J. Knauf and W.J. Laird. 1987. "Chemical Modification of Recombinant Interleukin 2 by Polyethylene Glycol Increases its Potency in the Murine Meth A Sarcoma Model," Proc. Natl. Acad. Sci. USA, 84:1487-1491.

Knauf, M.J. , D.P. Bell , P. Hirtzer , Z-P. Luo , J.D. Young and N.V. Katre. 1988. "Relationship of Effective Molecular Size to System Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with WaterSoluble Polymers," J. Biol. Chem., 263(29):15064-15070.

Katre, N. and M. J. Knauf. 1987. International Patent Application Number PCT/US86/01252.

Braatz, J.A. and A.H. Heifetz. 1992. "Polymer-Modified Peptide Drugs Having Enhanced Biological and Pharmacological Activities;' U.S. Patent 5,091,176.

Heifetz, A.H. , R.M. Barry , D.A. Miller , K. Yang and J.A. Braatz. 1991. "A New Synthetic Cell-Growth Enhancer," Clin. Biotechnol., 3(3)163-167.

Heifetz, A.H. , R.A. Wolfe , J.A. Braatz and N.P. Luthra. 1990. "Cell Growth Enhancers and/or Antibody Productions Stimulators Comprising Chemically Modified Hydrophilic Polyurea-Urethane Prepolymers and Polymers;' U.S. patent 4,929,706.